Gilead Sciences Acquires XinThera

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Pharmaceuticals

Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.

XenoTherapeutics Acquires Repare Therapeutics

January 28, 2026

Biotechnology

XenoTherapeutics, Inc. and Xeno Acquisition Corp. acquired all outstanding shares of Repare Therapeutics Inc. via a statutory plan of arrangement. The deal was approved by Repare shareholders in January 2026 and the acquisition was completed with a per-share cash payment of approximately US$2.20 plus contingent value rights.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Altaris Acquires WuXi AppTec's Advanced Therapies U.S. and U.K. Operations (including OXGENE)

December 24, 2024

Biotechnology

Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.

Gilead Sciences To Acquire Arcellx for $7.8 Billion to Strengthen CAR T-Cell Portfolio

February 21, 2026

Biotechnology

Gilead Sciences entered into a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a contingent value right of $5 per share, implying an equity value of about $7.8 billion. The deal is designed to give Gilead full control of Arcellx’s anito-cel (anito-cabtagene autoleucel) BCMA-directed CAR T therapy, eliminating profit-sharing and related payments while accelerating development and commercialization.